Medical technology company Enovis has launched the AltiVate Reverse Glenoid System, designed for reverse shoulder arthroplasty.
The system, which received FDA 510(k) clearance in May 2024, adds a bone-sparing baseplate and offers a range of modular options to cater to individual patient needs in reverse shoulder arthroplasty, including revisions.
Go deeper with GlobalData
It is based on Enovis’ central screw fixation design with at least ten years of clinical follow-up and introduces augmented baseplates to the AltiVate Reverse range, and features a modular baseplate with neutral and 15° wedge options.
The system also comprises multiple central compression screw lengths and diameters. Its design approach minimises bone removal and preserves the glenoid vault.
Furthermore, the AltiVate Reverse Glenoid System enhances Enovis’ reverse shoulder prosthesis (RSP) offerings by adding four new glenospheres.
This expansion gives surgeons an extensive selection to tailor the biomechanics to each patient, thereby aiming to optimise outcomes and extend the longevity of the implant.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataEnovis reconstructive business group president Louie Vogt said: “We are very pleased to offer a modular, augmented baseplate based on the proven central screw fixation principle of our legacy RSP system.
“This addition to our market-leading AltiVate Reverse continues our long history of surgeon-driven innovation and commitment to exceptional patient outcomes.”
Enovis said the inaugural procedure using the AltiVate Reverse Glenoid System was successfully performed by Dr Mark Frankle at Tampa General Hospital.
Frankle said: “The new AltiVate Reverse Glenoid is a major innovation for my practice.
“I now have one system with a variety of options to treat most, if not all, of my patients. It is simple and efficient while still offering the fixation and implant options I need, and it’s very exciting to be the first to use it clinically.”
Earlier this year, Enovis acquired surgical implant maker LimaCorporate to expand its global reach and portfolio of products.
The deal was signed between the parties in September 2023.
